BlueSphere Bio is leveraging its TCR discovery platform, TCXpress™, to develop a portfolio of TCR-based assets with an initial clinical focus on high-risk leukemias (AML, ALL, MDS). Under its TCX-101 program, BlueSphere anticipates dosing its first patient in 2024 with its first-in-human candidate, BSB-1001. BSB-1001 is a TCR T cell therapy targeting the minor histocompatibility antigen-1 to be used in conjunction with allogeneic hematopoietic stem cell transplant (alloSCT). The company has also discovered and nominated 3 additional miHA targeting TCRs for clinical development, all for use in the same clinical setting as BSB-1001, to become part of the TCX-101 Program as a panel with best-in-class population coverage. BlueSphere has also further broadened its AML therapy pipeline to address additional patients by discovering and nominating a lead TCR reactive against mutant NPM-1 for the TCX-102 program. The TCX-102 program is autologous and not given in combination with alloSCT.